1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLS
Aeolus Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
15,209.00Market Cap
Aeolus Pharmaceuticals, Inc.
AOLS
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
TTM
FRC
0.05
0.07
- -
0.04
0.02
- -
- -
- -
- -
- -
0.08
0.12
0.04
0.07
0.02
0.01
0.01
Revenue per Share
-27.78
-9.4
-2.88
-2.06
-0.49
-0.31
-0.1
-0.09
-0.07
-0.53
0.01
0.01
-0.03
- -
-0.02
-0.04
-0.03
Basic EPS, GAAP
-14.04
-6.8
-3.37
-1.03
-0.49
-0.26
-0.1
-0.06
-0.06
-0.05
-0.05
-0.01
-0.03
- -
-0.02
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-129.72
-91.77
-90.05
-16.7
-10.51
-8.06
-5.15
-4.96
-4.62
-3.71
-3.06
-2.92
-1.71
-1.36
-1.36
-1.27
-1.26
Book Value per Share
6.86
-11.17
-12.52
0.66
-0.07
0.09
0.04
-0.03
-0.03
-0.54
-0.39
-0.33
0.01
0.01
-0.01
0.02
- -
Tangible Book Value per Share
1
1
1
8
14
19
30
32
35
49
59
62
107
135
136
149
152
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
7
4
10
3
2
1
Sales/Revenue/Turnover
-18,384.09
-7,796.51
- -
-3,926.89
-2,752.78
-6,091.3
- -
- -
- -
- -
-80.94
-32.51
-68.69
-0.83
-84.41
-157.66
-531
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-22
-11
-3
-17
-7
-6
-3
-3
-2
-26
- -
2
-3
- -
-3
-4
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-50,484.09
-13,141.86
- -
-5,628.52
-2,740.08
-6,226.09
- -
- -
- -
- -
6.2
23.28
-81.67
-0.83
-84.47
-171.39
-531
Profit Margin (%)
4
-2
-2
6
- -
2
2
-1
- -
1
- -
-1
1
2
-1
3
- -
Working Capital
- -
1
1
1
1
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
6
-14
-17
6
-1
2
1
-1
-1
-27
-23
-20
1
2
-1
3
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.18
-0.94
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'17
Jun'17
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
152
152
152
Market Capitalization
29
14
14

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'17
Jun'17
Total Current Assets
3
2
1
Cash, Cash Equivalents & STI
2
1
- -
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
136.8%
-124.53%
-478.11%
Free Cash Flow
-79.15%
-154.75%
27.26%
Net Income, GAAP
415.57%
660.37%
35.39%
Sales/Revenue/Turnover
- -
9.87%
-33.27%
Total Cash Common Dividend
- -
- -
195.25%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
1
1
- -
1
3
2016
- -
1
1
1
2
2017
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
-0.01
-0.01
-0.01
- -
-0.02
2016
-0.01
-0.02
-0.01
- -
-0.04
2017
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
Similar Companies
Hikma Pharmaceuticals PLC (HKMPF)
Apontis Pharma AG (APPH.DE)
CF PharmTech, Inc. (2652.HK)
Sigachi Industries Limited (SIGACHI.BO)
Probi AB (publ) (PROB.ST)
RPG Life Sciences Limited (RPGLIFE.BO)
Business
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Mission Viejo, California, founded in 1996. The company develops a platform of novel compounds primarily for use in biodefense, fibrosis, oncology, infectious diseases, and diseases of the central nervous system. Its core products include AEOL 10150, a catalytic antioxidant under development as a medical countermeasure against pulmonary acute radiation syndrome (Lung-ARS) and the delayed effects of acute radiation exposure (DEARE), with additional indications in radiation oncology and idiopathic pulmonary fibrosis. Other compounds include AEOL 11114 for Parkinson's disease and epilepsy treatment and AEOL 20415, an orally available anti-infective agent. Aeolus has licensed approximately 180 compounds from institutions like the University of Colorado, Duke University, and National Jewish Health. Recent developments include process improvements and stability results for AEOL 10150 in a new formulation, as well as the continuation of development efforts supported by U.S. government contracts with the Biomedical Advanced Research and Development Authority (BARDA) and funding from the National Institutes of Health. These contracts focus on FDA approval pathways, such as pre-Emergency Use Authorization applications, and exploring uses against chemical gas and nerve agent exposure. The company’s strategic focus emphasizes leveraging government contracts to develop its lead compounds and expand indications. Aeolus Pharmaceuticals operates mainly in the United States and targets government biodefense programs, healthcare providers in oncology and fibrosis treatment, and neurological disorder therapeutics.